This article is Part 2 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1(link to article) provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class.
This short article takes a deeper look into the 2021 IPOs by technology and therapeutic class (small molecule vs. biotechnology) across the five most prevalent therapeutic areas: oncology, CNS, immunology, genetic diseases, and infectious diseases/other.
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: